Xponance Inc. Acquires 1,540 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Xponance Inc. lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 12.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,103 shares of the company’s stock after buying an additional 1,540 shares during the period. Xponance Inc.’s holdings in Hims & Hers Health were worth $341,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. State Street Corp lifted its stake in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after acquiring an additional 883,230 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Hims & Hers Health by 7.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company’s stock worth $43,448,000 after acquiring an additional 129,416 shares during the period. Finally, Yong Rong HK Asset Management Ltd acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $41,104,000. Institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 36,460 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $27.09, for a total value of $987,701.40. Following the sale, the chief executive officer now directly owns 27,918 shares of the company’s stock, valued at approximately $756,298.62. This represents a 56.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Melissa Baird sold 67,687 shares of Hims & Hers Health stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $34.84, for a total value of $2,358,215.08. Following the completion of the transaction, the chief operating officer now directly owns 751,243 shares of the company’s stock, valued at approximately $26,173,306.12. This trade represents a 8.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,061,718 shares of company stock worth $37,894,395 in the last quarter. 17.71% of the stock is owned by insiders.

Hims & Hers Health Trading Down 4.2 %

HIMS stock opened at $31.96 on Friday. The stock has a market capitalization of $7.10 billion, a P/E ratio of 72.63 and a beta of 1.37. The firm has a 50-day moving average price of $39.85 and a 200-day moving average price of $29.27. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Bank of America upped their target price on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday, March 18th. Finally, Citigroup reissued a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.